Dizal's ZEGFROVY Shows Striking Efficacy in Hard-to-Treat Lung Cancer

By Gary Clark

COPENHAGEN, Denmark – March 27, 2026 – A new targeted therapy is showing profound and potentially practice-changing results for a group of non-small cell lung cancer (NSCLC) patients who have long faced limited treatment options and a poorer prognosis. Data presented this week at the 2026 European Lung Cancer Congress (ELCC) revealed that Dizal's drug, ZEGFROVY® (sunvozertinib), achieved a remarkable 81.3% objective response rate (ORR) when used as a first-line monotherapy for patients with advanced NSCLC harboring specific, difficult-to-treat genetic mutations.

The findings, which have generated significant buzz among oncologists, address a critical unmet need for patients whose tumors are driven by EGFR P-Loop and αC-helix compressing (PACC) mutations or other uncommon EGFR variants. For this population, every single patient in the study saw their tumors shrink, and the disease was brought under control in 100% of cases.

A New Standard for an Underserved Population?

For years, the treatment of EGFR-mutated NSCLC has been a story of two different realities. Patients with 'classical' mutations, such as exon 19 deletions or L858R, have benefited from a series of highly effective EGFR tyrosine kinase inhibitors (TKIs), with drugs like osimertinib becoming a first-line standard of care. However, the 10-15% of patients with 'uncommon' mutations—a diverse group including the PACC classification—have not been so fortunate.

These uncommon mutations often respond poorly to existing TKIs, leaving patients with chemotherapy as their primary, and often only, effective option. This has resulted in a significant disparity in outcomes. The new ZEGFROVY data challenges this paradigm directly.

Presented at ELCC, the results from the investigator-assessed study were striking:

• Objective Response Rate (ORR): 81.3% of patients saw a significant reduction in tumor size, a figure that stands in stark contrast to the more modest response rates seen with other TKIs in this patient group, which often range from 40% to 60%.
• Disease Control Rate (DCR): An unprecedented 100% of patients experienced either tumor shrinkage or disease stabilization, indicating that the drug had a biological effect in every participant.
• Intracranial Activity: The drug demonstrated a powerful ability to cross the blood-brain barrier, a critical hurdle for lung cancer therapies. Among 15 patients who had brain metastases at the start of the trial, 11 showed a tumor response in the brain, offering new hope for controlling this common and dangerous site of disease spread.

The durability of these responses is also promising. At the time of data analysis, the median duration of response had not yet been reached, with over 81% of patients remaining on treatment. The estimated 9-month progression-free survival rate was a robust 83.9%, suggesting the treatment's benefits are sustained over time. Importantly, the therapy was well-tolerated, with a manageable safety profile consistent with prior studies and no new safety concerns emerging.

The Science of a Broad-Spectrum Inhibitor

ZEGFROVY's success in this challenging patient population stems from its molecular design. Developed by scientists at Dizal, it is an irreversible EGFR inhibitor engineered to target a wide spectrum of EGFR mutations while largely sparing healthy, wild-type EGFR. This selectivity is key to its potent efficacy and manageable side-effect profile.

This broad activity is a significant scientific achievement. While many targeted therapies are designed for exquisite specificity to a single mutation, ZEGFROVY's versatility allows it to effectively inhibit a range of mutations that have historically been resistant to other drugs. This versatility is not just theoretical; ZEGFROVY is already approved in both the United States and China for a different challenging mutation, EGFR exon 20 insertion (exon20ins), in patients whose disease has progressed after chemotherapy.

Furthermore, Dizal recently announced that a Phase 3 study (WU-KONG28) evaluating ZEGFROVY as a first-line treatment for the exon20ins population met its primary endpoint, outperforming standard chemotherapy. This growing body of evidence paints a picture of ZEGFROVY as a uniquely versatile agent in the fight against EGFR-mutated lung cancer, capable of tackling multiple, distinct drivers of the disease.

Navigating the Competitive and Regulatory Landscape

The new data positions ZEGFROVY favorably in a market that is actively seeking better solutions for uncommon EGFR mutations. While drugs like afatinib have shown some activity and gained approval for specific uncommon mutations, their efficacy can be variable. ZEGFROVY's high response rate across a broader group, including PACC mutations, could make it a preferred option if it gains regulatory approval.

The impressive intracranial activity also provides a potential edge, as controlling brain metastases is a primary goal of NSCLC treatment. Oncologists are increasingly looking for therapies that can treat the entire patient, including the central nervous system, from the outset.

Dizal's prior success with regulators may also smooth the path forward. The company has already navigated the U.S. FDA and Chinese regulatory systems, securing accelerated approvals and Breakthrough Therapy Designations for ZEGFROVY in the exon20ins setting. These designations are reserved for drugs that demonstrate substantial improvement over available therapies for serious conditions. Given the high unmet need and the strength of the new data, a similar expedited pathway for the PACC and uncommon mutation indication seems plausible.

"NSCLC patients with EGFR PACC and other uncommon mutations represent a population with substantial unmet medical need, given the limited availability of effective and well-tolerated target therapies," said Dr. Xiaolin Zhang, CEO of Dizal, in a statement. "The data presented at ELCC further reinforces the potential of ZEGFROVY to address this gap."

The company has expressed its commitment to advancing its clinical programs and engaging with regulatory authorities to bring this potential new treatment option to patients globally. As Dizal continues to build its commercial presence in the U.S. and Europe, the expanding portfolio for ZEGFROVY could transform it from a niche product into a cornerstone therapy in the multi-billion dollar EGFR NSCLC market.

For now, the data from Copenhagen offers a tangible sense of optimism for a patient community in dire need of a breakthrough. The results underscore the critical importance of comprehensive molecular testing, such as next-generation sequencing (NGS), to identify not just common but also these rare mutations, ensuring that patients can be matched with the most effective therapies as they become available. The path from clinical trial to standard clinical practice is long, but for patients with uncommon EGFR mutations, that path now looks significantly brighter.